Takeda’s Livtencity (maribavir) Receives the EC’s Marketing Authorization for the Treatment of Post-Transplant Cytomegalovirus Infection
Shots:
- Livtencity received the marketing authorization from the EC to treat CMV that are refractory to ≥1 prior therapy in adult patients undergoing HSCT or SOT
- The authorization was based on the P-III (SOLSTICE) trial evaluating Livtencity vs conventional antiviral therapies in a ratio (2:1) in 352 patients The 1EPs confirmed CMV DNA level <LLOQ in 2 consecutive samples separated by 5 days @8wk. while 2EPs was CMV DNA level <LLOQ and CMV inf. symptom control with the maintenance of treatment effect through 16wk.
- The EC’s marketing authorization is valid in all EU member states, Iceland, Liechtenstein, Norway & Northern Ireland. Livtencity is 1st oral treatment to block the natural substrates of the CMV-specific UL97 protein kinase
Ref: Businesswire | Image: Takeda
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
